Tag: mental health

How therapy has turned generation of Americans into ‘victims’ and may be CAUSING depression epidemic, according to top experts

There has been a big push to get more Americans talking about their feelings in recent decades.

But now experts are starting to wonder if the widespread use of therapy may be having the opposite effect and actually fueling America’s depression crisis.

They argue the treatment, however well-intentioned, can instill a ‘victim’ mentality where people become hyper-focused on their feelings and less engaged with the world around them, making them more depressed.

Around a quarter of US adults said they had visited a therapist or psychiatrist in 2022, which is twice as high as 20 years ago and far higher than the around 3 percent in the UK.

Therapy speak has become so common it has permeated mainstream culture in the US. Clinical words used during counseling like ‘gaslighting’, ‘trauma’ and ‘microaggressions’ have become household terms.

Professor Robert Dingwall, a social scientist and adviser to the UK government, told DailyMail.com that looking on at the situation in America, there is a concern among sociologists that people are being referred to therapy at the slightest sign of hardship in their life. 

‘There is a tendency to medicalize everyday problems in pursuit of commercial interests,’ he said, whether it be rejection from a partner or a failed job interview.

‘This is something that people have been saying for 50 or 60 years, a concern that’s been expressed by both psychiatrists and sociologists.’ 

This fosters a victim mentality, said Shawn Smith, a clinical psychologist based in Colorado.

Keep reading

New Study Finds One Dose of LSD Could Effectively Treat Anxiety in Many Patients

After years of criminalization and marginalization, scientists have begun looking at LSD’s medical benefits more closely, so much so that the Food and Drug Administration just issued a groundbreaking stamp of approval. 

Biopharmaceutical company Mind Medicine announced March 7 that the FDA has awarded “breakthrough therapy” status to its trial of patients using MM120 (lysergide D-tartrate) to treat anxiety. MindMed chief medical officer Daniel Karlin explained what the trial approval means going forward. “A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need with morbidity and mortality associated with it,” he told CNN. The move allows the FDA to “engage more closely in drug development” and speeds up the road to final approval as the agency is involved throughout the process. 

MM120 is the codename for MindMed’s lysergide D-tartrate compound, which resembles and delivers similar effects to lysergic acid diethylamide, known more commonly as LSD. In its ongoing trial, which kicked off in 2022, MindMed has so far found that a single dose of MM120 led to a 48-percent rate of remission from generalized anxiety disorder after 12 weeks following the drug’s administration. Scientists also noted significantly improved clinical signs of generalized anxiety disorder among 65 percent of patients within three months. 

“The clinical improvement for many patients was more than double what we see with today’s standard of care,” Karlin said. “This occurred at all levels of anxiety, from moderate all the way up to severe.”

Keep reading

Single LSD dose provides lasting anxiety relief: Research

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to an LSD formula to treat generalized anxiety disorder after an initial study has shown that a single dose of the drug could provide lasting relief.

The LSD therapy developed by Mind Medicine Inc. (MindMed) must still go through the standard FDA approval process and will soon enter Phase 3 clinical trials.

The study that prompted FDA advancement found the drug was “generally well-tolerated with most adverse events rated as mild to moderate, transient and occurring on dosing day, and being consistent with expected acute effects of the study drug,” according to a release on the findings.

The most common adverse effects on the initial “dosing day” — or when patients were first given the drug — included hallucinations, euphoric mood, abnormal thinking, headache, dizziness and nausea, among others.

The company plans to meet for an update with the FDA in the coming months and begin an expanded clinical program in the second half of the year.

MindMed, a pharmaceutical company focused on developing psychedelic drugs into medicines, has spent years researching possible medicinal uses for LSD, an illicit drug that has never been approved for medicinal use. The specific LSD formula from the study is dubbed MM120.

Keep reading

Analysis: Cannabis Products Provide Sustained Improvements In Sleep Quality For Patients With Insomnia

Insomnia patients who consume cannabis products report sustained improvements in their sleep quality, according to data published in the journal Brain & Behavior. 

British investigators assessed the safety and efficacy of plant-derived cannabis products (either oils, flower, or a combination of both) in over 60 patients enrolled in the UK Medical Cannabis Registry. Cohort participants possessed a doctor’s authorization to access cannabis products. (Since 2018, specialists have been permitted to prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Authors assessed the efficacy of cannabis at one, three, and six months.

Researchers reported that cannabis products were “well tolerated” and that they were associated with better sleep, reduced anxiety, and greater quality of life. 

They concluded: “More than 40 percent of participants who completed each PROM [patient-reported outcome measure] round reported clinically significant improvement in their sleep quality at each time period. These results show that initiation of CBMP [cannabis-based medicinal products] therapy was associated with improvements in those patients who had previously failed to respond to currently licensed treatments for insomnia.”

Keep reading

New Mexico Senate Passes Psilocybin Therapy And Research Resolution In Unanimous Vote

The New Mexico Senate has unanimously approved a bipartisan resolution requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.

The body voted 37-0 to pass the measure from Senate Minority Whip Craig Brandt (R) and Sen. Jeff Steinborn (D).

The action came days after the Health and Public Affairs Committee had approved the legislation, also unanimously.

As “memorial” legislation, the proposal isn’t binding. Rather, it would represent a formal request for the state Department of Health to “study the efficacy of using psilocybin mushrooms for therapeutic treatments and the establishment of a program for psilocybin mushrooms to be used for therapeutic medical treatments.”

The whereas section of the resolution cites various studies supporting the therapeutic benefits of psilocybin for conditions such as major depression and substance misuse, while pointing out that the federal Food and Drug Administration (FDA) has designated the psychedelic as a “breakthrough therapy.”

To that end, the measure states that the health department should look into “necessary statutory or regulatory framework for developing” a state-level psilocybin program.

Keep reading

New Mexico Senate Committee Unanimously Approves Psilocybin Therapy And Research Resolution

A New Mexico Senate committee has unanimously approved a bipartisan resolution requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.

The Senate Health and Public Affairs Committee voted 7-0 to pass the resolution from Senate Minority Whip Craig Brandt (R) and Sen. Jeff Steinborn (D) on Saturday.

As “memorial” legislation, the bicameral proposal wouldn’t be binding. Rather, it would represent a formal request for the state Department of Health to “study the efficacy of using psilocybin mushrooms for therapeutic treatments and the establishment of a program for psilocybin mushrooms to be used for therapeutic medical treatments.”

The whereas section of the resolution cites various studies supporting the therapeutic benefits of psilocybin for conditions such as major depression and substance misuse, while pointing out that the federal Food and Drug Administration (FDA) has designated the psychedelic as a “breakthrough therapy.”

To that end, the measure states that the health department should look into “necessary statutory or regulatory framework for developing” a state-level psilocybin program.

“This can help people very potentially, and so what we’re trying to do in a bipartisan way is ask the Department of Health to recognize that we want them to get going to start looking at this,” Steinborn said during Saturday’s committee hearing.

The measure “really seeks to expand therapeutic options for New Mexicans,” he said.

Keep reading

THE WEIRD AND WONDERFUL WORLD OF LSD

LSD is a drug which has had a bizarre inception and nuanced history. What began as a pharmacological experiment rapidly evolved into a substance which was used for a wide range of uses. From groundbreaking psychiatric work all the way to abuse in mind control military projects, let’s dive into some of the most significant examples of psychedelics’ use in society since its creation.

Hofmann’s Accidental Ingestion

Dubbed as the father of the psychedelic movement due to his work on the synthesis of LSD, Albert Hofmann was the first to produce and ingest LSD. Albert Hofmann first synthesised Lysergic Acid Diethylamide (LSD) in November 1938 when studying the medicinal properties of the ergot fungus and the Mediterranean squill. Ergot is a fungus which grows on rye and can infect the grain causing muscle spasms, delusions, hallucinations, gangrenous symptoms and ultimately death to those who consume it. This process has been linked to plagues and famines which have killed hundreds of thousands of people in the past. 

Hofmann’s boss, Arthur Stoll, managed to isolate the toxic compounds in ergot: ergotamine and ergobasine. By utilising Aotamine, the medicinal compound in ergot, Stoll was able to produce medicines for his Swiss pharmaceutical company Sandoz. 

Hofmann originally intended for LSD to be used as a respiratory and circulatory stimulant. However, when he accidentally absorbed the drug in his lab in 1943, he discovered that it had a far more powerful impact on his state of consciousness. Hofmann originally was unsure of how he had experienced the effects, and believed that LSD couldn’t have been the cause for his symptoms as he had been meticulous in avoiding contamination due to his knowledge of the lethality of ergot. However, he attempted to reproduce his effects by consuming what he believed to be a miniscule dose of LSD to test whether it was the cause.

Keep reading

Military Veterans Who Received Psychedelic Ibogaine Treatment Saw ‘Dramatic’ And ‘Life-Changing’ Improvements In PTSD And Depression, Stanford Study Finds

Military combat veterans with traumatic brain injuries (TBI) saw “dramatic” and “life-changing” improvements in their symptoms and cognitive functioning immediately after receiving treatment with the psychedelic ibogaine, new research shows.

Stanford University researchers behind the study, which was published in the journal Nature Medicine last week, followed 30 veterans who were functionally disabled from symptoms of TBI such as post-traumatic stress, depression and anxiety and who had a history of repeated blast or combat exposures.

The team, which collaboration with the foundation VETS, Inc., assessed the veterans before and after they visited a clinic in Mexico to receive ibogaine treatment, and they identified profound changes in the participants’ mental health, with minimal side effects.

Prior to the treatment, the veterans each met the criteria for clinically significant levels of disability. Twenty-three had diagnosable PTSD, 14 had anxiety disorder, 15 had alcohol use disorder and 19 had been suicidal at some point in their lifetimes.

After receiving ibogaine, in addition to magnesium to protect against potential heart-related complications, there was an immediate “remarkable reduction” in symptoms, “with large effect sizes” that sustained over time.

Keep reading

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next

Psychedelics made their mark this year—not as counterculture party drugs, but as a new paradigm in mental health therapy.

In June, Australia became the first country to greenlight MDMA, popularly known as molly or ecstasy, and psilocybin, the active ingredient in magic mushrooms, to treat post-traumatic stress disorder (PTSD) and depression.

MDMA also inched closer to approval in the US for PTSD, thanks to positive results from a large multi-site, double-blind, randomized trial—the gold standard for testing drug safety and efficacy.

Meanwhile, psilocybin gained steam as a treatment for severe depression. A randomized, placebo-controlled trial in 104 adults found that a single dose of magic mushrooms dampened the symptoms of depression when combined with psychological support. The effects lasted at least six weeks with minimal side effects. Clinical trials are in the works to explore whether psilocybin and its derivatives can help patients cope with chronic lower back pain, tackle depression in bipolar disorder, and ease mental struggles in end-of-life care.

This year also saw magic mushrooms for therapy move ahead. Registered clinics in Oregon have already begun psilocybin treatments in patients with mental health disorders ranging from obsessive-compulsive disorders to PTSD—even though the drug isn’t federally approved and remains illegal.

In 2022, Oregon became the first state to legalize psilocybin therapy with strict regulations: The mushrooms are carefully controlled for potency and quality and need to be taken under supervision. The guidelines offer a blueprint for other states—such as Colorado, which also decriminalized psilocybin for potential therapeutic use.

Yet one glaring problem remains. Despite promising clinical results, no one knows exactly how psychedelic drugs work in the brain. Examining their actions on brain cells isn’t just an academic curiosity. It could give rise to variants that maintain antidepressant properties without the high. And because hallucinogens substantially alter our perception of the world, they could be powerful tools for investigating the neurobiology behind consciousness.

Keep reading

New Hampshire Republican Unveils Bill To Legalize Psychedelics For Mental Health And Medical Conditions

A Republican lawmaker in New Hampshire has prefiled legislation for the coming session that would legalize three psychedelic substances—psilocybin, LSD and mescaline—for therapeutic use with a healthcare provider’s recommendation.

The bill, HB 1693, from Rep. Kevin Verville, would create a regulated psychedelics system for registered patients, with alternative treatment centers (ATCs) set up to produce and dispense the substances.

The proposal is modeled after the state’s existing medical cannabis law, under which seven licensed marijuana ATCs currently serve patients. Psychedelics patients would be required to obtain state-issued ID cards, while designated caregivers could purchase and provide the substances to patients.

To access psychedelics, patients would need a recommendation from a licensed physician, advanced practice nurse, physician’s assistant, nurse practitioner or mental health provider. Anyone falsely claiming to be using psychedelics legally under the measure would be subject to a civil violation and $500 fine, in addition to other penalties.

Among the qualifying conditions envisioned for the program are anxiety, depression, PTSD, panic disorder, obsessive-compulsive disorder, social anxiety, body dysmorphia, eating disorders, sleep disorders, substance use disorder, chronic pain, attention deficit, migraines and cluster headaches, postpartum mental illnesses and others.

The proposal would also allow providers to recommend psychedelics for “any novel or emergent illness which is not categorized in the Diagnostic and Statistical Manual of Mental Disorders but is diagnosed by a state licensed mental health professional,” though there would need to be published scientific observations, including self-reports, regarding psilocybin as a treatment for the condition.

The new program would be overseen by the state Department of Health and Human Services—though the measure does not contain appropriations to fund the program’s startup or staff, a legislative description says, noting that fees for patients and ATCs would be necessary to cover those costs.

Keep reading